文献速递血栓与止血

诱发性静脉血栓栓塞症的复杂性:一种治疗方案并不适合所有患者

The complexity of provoked venous thromboembolism: one treatment plan does not fit all.
PubMed 文献 · Blood Adv · 2026-01-01

本文综述了诱发性静脉血栓栓塞症(VTE)抗凝疗程决策的复杂性,指出短暂性危险因素分为主要和次要因素,且主要因素复发风险低于次要因素;持续性危险因素进一步增加复发风险,部分如炎症性肠病指南推荐无限期抗凝。HI-PRO试验发现延长血栓预防可降低复发VTE风险,但研究人群异质性和样本量小无法确定哪些亚组可安全停药。

要点

  • 短暂性危险因素分主要(如关节置换)和次要(如长途旅行),主要因素复发风险更低。
  • 持续性危险因素如炎症性肠病复发风险高,指南推荐无限期抗凝。
  • HI-PRO试验显示延长血栓预防降低复发VTE风险,但样本小无法确定安全停药亚组。

核心结论

  • 诱发性VTE的抗凝疗程需根据危险因素类型个体化决策,一种方案不适合所有患者。

研究设计与样本

  • 综述性文章,结合HI-PRO试验等证据讨论诱发性VTE的抗凝决策。

主要发现

  • 主要短暂性危险因素(如关节置换)的复发VTE风险低于次要短暂性危险因素(如长途旅行)。
  • 持续性危险因素(如炎症性肠病)复发风险高,指南推荐无限期抗凝;其他持续性因素(如慢性肾功能不全、肥胖)复发风险较低。
  • HI-PRO试验发现延长血栓预防队列复发VTE风险更低,挑战传统限时治疗。

关键数值与推荐

  • 炎症性肠病等持续性危险因素复发VTE风险足够高,指南推荐无限期抗凝。

临床怎么用

  • 临床需评估VTE危险因素类型(主要/次要短暂性、持续性)及复发风险,个体化决定抗凝疗程。

局限性

  • HI-PRO试验研究人群异质性和样本量小,无法确定哪些患者亚组可安全停用抗凝。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The decision of whether to continue patients diagnosed with venous thromboembolism (VTE) on anticoagulation after the initial treatment period is often nuanced. Many patients will have ≥1 transient risk factor associated with a time-limited increased risk of VTE. Transient risk factors are further divided into major factors, such as joint replacement, or minor factors, such as prolonged travel, which determine the magnitude of risk for an initial VTE. In addition, major transient risk factors generally carry a lower risk of recurrent VTE than minor transient risk factors. However, many patients will also have ≥1 persistent VTE risk factor, which further increase the risk for recurrence. Some persistent risk factors, such as inflammatory bowel disease, are associated with a sufficiently high risk of recurrent VTE, for which guidelines recommend indefinite anticoagulation. There are multiple other persistent risk factors that carry a lower risk of recurrent VTE, such as chronic renal insufficiency and obesity. The HI-PRO (High-Risk Patients with Provoked Venous Thromboembolism) trial sought to assess the efficacy and safety of extended thromboprophylaxis for the prevention of recurrent VTE in patients with an initial provoked VTE and at least 1 persistent risk factor. The study found a lower risk of recurrent VTE in the thromboprophylaxis cohort, challenging the traditional time-limited treatment for provoked VTE, but heterogeneity of the study population and small sample size preclude identification of which subsets of patients could safely discontinue anticoagulation. We consider the conundrum of provoked VTE in this review.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Peseski AM, Kapoor S, Ortel TL, et al. The complexity of provoked venous thromboembolism: one treatment plan does not fit all. Blood Adv. 2026. PMID: 42679342. doi:10.1182/bloodadvances.2025018610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。